Andrew Cheng, Akero Therapeutics CEO
June 5, 2023 11:19 AM EDT
R&D

Akero’s NASH can­di­date re­duces liv­er fat in pa­tients tak­ing a GLP-1

Paul Schloesser

Associate Editor

Akero Ther­a­peu­tics said its NASH drug re­duced liv­er fat in pa­tients who were al­so tak­ing a GLP-1 ag­o­nist.

The NASH-fo­cused biotech on Mon­day

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Chi­na’s biotech mar­ket is stag­ing a come­back that US biotech can on­ly wish for

Bris­tol My­er­s' schiz­o­phre­nia drug fails Phase 3 tri­al for ad­junc­tive treat­ment

Genen­tech vet launch­es ADC start­up with $20M

With aims to be­come a 'gen­er­a­tional biotech,' Zealand Phar­ma hires Lil­ly vet­er­an as sci­ence chief

As­cle­tis posts puz­zling Phase 1 up­date on obe­si­ty pill

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times